For many cancer patients and their households, the questions that take centre stage after their analysis and subsequent line of remedy are: ‘What are the treatment options available’, ‘what clinical trials could one participate in’ and ‘who are the experts for a particular cancer type’.
To have entry to personalised solutions to such questions, CURIA, an application-based platform, seeks to empower cancer patients and their households with data to steer their cancer journey.
Developed by AI firm Innoplexus in June final yr, the applying has been downloaded greater than 175,000 occasions globally. After profitable launches in Germany, Italy, Spain, Switzerland and France, CURIA was launched in India in April, the place it has gained greater than 70,000 lively customers in three months.
“When my best friend and mentor was diagnosed with cancer, we went through his treatment journey and had questions. We searched for answers online and here it became all too clear that this information is not easy to find. This is the experience of millions of people diagnosed with cancer. We founded Innoplexus, an AI company, driving drug discovery together with pharma companies and biotechs in 2015. Out of this came CURIA, an app which helps them navigate their cancer journey,” mentioned Dr Gunjan Bhardwaj, founder and CEO, Innoplexus, Germany.
The utility is constructed over the OncoCoin platform, which makes use of AI expertise to look 95 per cent of the web for updates to registries, drug approval websites, and scientific trial databases. Patients registered with the applying reply a questionnaire about their cancer kind, stage and demographics. Then they obtain details about therapies, scientific trials and specialists tailor-made to their oncological profile. The data can also be consistently reviewed by a group of specialists earlier than it’s supplied to the affected person. Physicians can have a broad overview of accessible scientific trials for his or her affected person with inclusion and exclusion standards. Together with their patients, they will submit purposes for scientific trials, making the method simpler.
“All patients should have access to the information they need to make decisions together with their doctor. But like many illnesses, cancer is still considered a taboo in India, which makes it difficult for patients and their families to get access to authentic information and care. According to one study, 70 per cent of cancer patients are dissatisfied with the information they receive,” mentioned Amit Ananpara, Innoplexus India co-MD, based mostly in Pune.
Cancer circumstances in India and globally are on the rise and there are steady improvements in cancer therapies and progressive scientific trials, he mentioned. “For the medical fraternity, the advancements move so fast, it is difficult to keep up with who is running the most innovative trials, where, and what the latest treatments are. Tools such as CURIA are important to ensure oncologists are open to discussing patients’ options with them,” added Ananpara.
For the applying to succeed in the grassroot degree, it can quickly be out there in additional regional languages in India, mentioned Ananpara. It is at present out there in English, German, Spanish, French and Italian. Bhardwaj added that shifting ahead, CURIA may have a second opinion service particularly for patients in India to get the very best line of remedy as per their wants.
Apart from a powerful AI spine and easy consumer interface, CURIA’s standard characteristic ‘Cancer Twin’ permits patients with comparable oncology profiles to share experiences and empower one another over non-public chats. The algorithm matches patients with probably the most comparable different cancer profiles and the chats are encrypted by blockchain.
Talking about cancer turning into the ‘Forgotten Big C’ amid the pandemic, Bhardwaj mentioned that circumstances have gone undiagnosed, therapies have been delayed and psychological well being of cancer patients who’ve needed to isolate has deteriorated. “The app served a much needed resource for patients who have had doctor’s appointments cancelled or experienced reduced access to treatment resulting from the pandemic. The app helped patients from the mental health perspective, matching the most similar patients to each other so they could share experiences privately,”
Bhardwaj mentioned that digital well being had a sluggish progress curve earlier than the pandemic and although it has been clear that telemedicine and apps for patients to handle their well being have been wanted for a very long time, the pandemic has considerably sped up the tempo of adoption.
“Apps such as CURIA alleviate the healthcare system as patients have access to reliable, tailored information beyond the doctor’s office to help them understand their disease and options. It also reduces the need for in-hospital appointments. Further, when the healthcare focus has been on other topics, it helps patients understand what the best treatment options could be for them…,” he mentioned.